GlassScriptPhysician profile
Amy A Waller
NPI 1255358875
$5,840.74
in general payments reported to CMS, 2019-2025
25 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $574 · 2022: $816 · 2023: $1,582 · 2024: $1,808 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,361 · Education: $89.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,361.08 |
| Education | $89.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,395.91 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,185.47 | 2021-2024 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $734.53 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $704.69 | 2021-2025 | Stelara, Tremfya, Remicade |
| Regeneron Healthcare Solutions, INC. | $587.71 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $223.91 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $180.96 | 2022-2024 | Dificid |
| Genzyme Corporation | $121.21 | 2022-2023 | |
| Pfizer INC. | $105.28 | 2021-2025 | |
| Madrigal Pharmaceuticals | $72.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Grt US Holding, INC. | $71.44 | 2022 | |
| Lilly USA, LLC | $59.46 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $53.60 | 2023-2025 | Vegzelma, Yuflyma |
| Ferring Pharmaceuticals INC. | $52.01 | 2023-2024 | Rebyota |
| Celgene Corporation | $47.02 | 2021-2023 | Zeposia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $34.13 | 2023-2024 | Idacio |
| Phathom Pharmaceuticals, INC. | $32.25 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $30.38 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $25.90 | 2021 | |
| Amgen INC. | $24.79 | 2023 | Avsola, Amjevita |
| Ucb, INC. | $24.25 | 2024 | Bimzelx |
| Ipsen Biopharmaceuticals, INC | $23.18 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.19 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $17.77 | 2021 | |
| Exact Sciences Corporation | $14.23 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Waller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.